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MicroRNA miR-425 is a negative regulator of
atrial natriuretic peptide
Pankaj Arora1,2,3,4, Connie Wu5, Donald B Bloch6,7, Brandi N Davis-Dusenbury8, Ester Spagnolli5, Akiko Hata9,
Sara Vandenwijngaert10, Melissa Swinnen10, Stefan Janssens10, Emmanuel S Buys5, Kenneth D Bloch1,2,5*†,
Christopher Newton-Cheh1,2,3,4†, Thomas J Wang1,2†
From 6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Erfurt, Germany. 28-30 June 2013
Background
Numerous common genetic variants have been linked to
blood pressure, but no underlying mechanism has been
elucidated. Population studies have revealed that a genetic
variant, rs5068 (A/G), is associated with blood pressure
and the risk of hypertension. rs5068 lies in the 3’ untrans-
lated region (3’UTR) of NPPA, the gene encoding atrial
natriuretic peptide (ANP), and presence of the minor G
allele is associated with increased circulating ANP levels
and reduced blood pressure.
Results
We hypothesized the existence of a microRNA (miR) that
targets the NPPA 3’UTR and that the binding of the miR
to the NPPA 3’UTR would be disrupted in transcripts
from the rs5068 minor allele. We identified a microRNA,
miR-425, that is predicted to bind the sequence spanning
rs5068 for the A, but not the G, allele. miR-425 is
expressed in human atria and ventricles. Using luciferase-
3’UTR reporter constructs, we observed that miR-425
could silence reporter mRNAs carrying the NPPA major
allele 3’UTR, but not those carrying the minor allele
3’UTR. Similarly, an anti-miR directed against miR-425
augmented expression of the luciferase-NPPA 3’UTR con-
struct containing the major allele but not the minor allele.
miR-425 reduced NPPA mRNA levels and ANP synthesis
in human cardiomyocytes derived from induced pluripo-
tent stem cells.
Conclusion
Our studies provide mechanistic insights into how a
common genetic variant identified in population genetic
studies can regulate ANP levels and blood pressure.
miR-425 is a novel regulator of ANP production, raising
the possibility that miR-425 antagonists could be used to
treat disorders of salt overload, including hypertension
and heart failure.
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